What is it about?
Rheumatoid arthritis (RA) is a chronic autoimmune disease where joint inflammation is driven by immune cell infiltration and endothelial dysfunction, leading to joint damage. This study identifies the Reelin protein and its receptor Apoer2 as key players in promoting endothelial activation and immune cell migration into joints during RA. By targeting the Reelin/Apoer2 pathway through genetic disruption or therapeutic inhibition using the CR-50 antibody, researchers demonstrated significant reductions in inflammation, immune cell infiltration, and joint damage in multiple mouse models of arthritis, with effects comparable to the commonly used anti-inflammatory drug diclofenac but without its gastrointestinal side effects. Elevated Reelin levels were also observed in RA patients, correlating with disease severity and inflammatory markers, suggesting its potential as a biomarker. These findings highlight the Reelin/Apoer2 pathway as a promising, non-immunosuppressive therapeutic target for RA and other inflammatory diseases, offering an alternative to current immune-based treatments with fewer side effects.
Featured Image
Photo by roger vaughan on Unsplash
Why is it important?
The study addresses a significant gap in the treatment of rheumatoid arthritis (RA), a chronic autoimmune disease that affects millions worldwide. While current therapies target the immune system, they often come with side effects, limited efficacy, or loss of effectiveness over time. This research identifies the Reelin/Apoer2 signaling pathway as a previously unexplored mechanism driving joint inflammation by promoting endothelial dysfunction and immune cell infiltration. By disrupting this pathway either genetically or through a therapeutic antibody (CR-50), the study demonstrates significant reductions in inflammation, joint damage, and systemic inflammatory markers in preclinical models, without the side effects associated with conventional treatments like NSAIDs. Furthermore, elevated Reelin levels in RA patients suggest its potential as both a biomarker for disease severity and a novel therapeutic target. This innovative approach shifts focus from immunosuppression to restoring vascular health, offering safer and potentially more effective treatment options for RA and other inflammatory diseases.
Perspectives
The perspectives of this research highlight its potential to address critical challenges in rheumatoid arthritis (RA) treatment. Current therapies primarily target the immune system, which can lead to significant side effects, limited efficacy, or loss of effectiveness over time. This study introduces a novel approach by targeting the Reelin/Apoer2 pathway, focusing on endothelial dysfunction, a key driver of inflammation in RA. By disrupting this pathway genetically or therapeutically, the research demonstrates substantial reductions in joint inflammation and damage in preclinical arthritis models, comparable to conventional treatments like diclofenac but without associated side effects. The findings suggest that Reelin could serve as both a biomarker for disease progression and a therapeutic target, offering a safer, non-immunosuppressive alternative for managing RA. Moreover, the potential applicability of this approach extends beyond RA to other chronic inflammatory diseases, such as multiple sclerosis and atherosclerosis, emphasizing its broader impact. This work represents an important step towards developing innovative, targeted therapies that improve patient outcomes while minimizing risks.
Laurent Calvier
Read the Original
This page is a summary of: Genetic or therapeutic disruption of the Reelin/Apoer2 signaling pathway improves inflammatory arthritis outcomes, Proceedings of the National Academy of Sciences, March 2025, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2418642122.
You can read the full text:
Contributors
The following have contributed to this page
